Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Central Nervous System Neoplasms 3Brain Neoplasms 3Glioma 2Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Skin Neoplasms 1Sarcoma 1Pinealoma 1Neuroma, Acoustic 1Neoplasms, Germ Cell and Embryonal 1Mouth Neoplasms 1Meningioma 1Melanoma 1Medulloblastoma 1Glioblastoma 1Ependymoma 1Craniopharyngioma 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Astrocytoma 1

Interventions

HhAntag691 21Biopsy 11Imiquimod 10Aminolevulinic Acid 9sonidegib 8Photochemotherapy 8Nivolumab 81-phenyl-3,3-dimethyltriazene 7methyl 5-aminolevulinate 6cemiplimab 6Surgical Procedures, Operative 5Specimen Handling 5Radiotherapy 5Itraconazole 5pembrolizumab 4daromun 4Mohs Surgery 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Curettage 4Tomography, Optical Coherence 3Standard of Care 3Niacinamide 3Microscopy, Confocal 3IPI-926 3CTLA-4 Antigen 33-ingenyl angelate 3tazarotene 2talimogene laherparepvec 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Basal Cell × tozuleristide × Clear all
NCT02097875 2015-04-21

Safety Study of a Fluorescent Marker to Visualize Cancer Cells

Blaze Bioscience Australia Pty Ltd

Phase 1 Completed
21 enrolled
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡